亚历山大病:潜在的药物点和未来的方向
Emily Zavala1, Tahl Zimmerman2
1Biomedical Sciences Program, Department of Physician Assistant Studies, High Point University, High Point, NC, USA. ezavala@highpoint.edu.
Molecular neurobiology
|May 31, 2025
概括
亚历山大病是一种罕见的致命神经退行性疾病,涉及GFAP基因问题. 本综述探讨了降低GFAP的潜在药物标,提供了超越基因淘汰的新治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 亚历山大病 (AxD) 是一种罕见的,致命的神经退行性疾病.
- 它的特点是质纤维酸性蛋白 (GFAP) 基因上调和罗森塔尔纤维形成.
- GFAP是成熟星细胞的标记物,其调节失调导致反应性星病,与神经退行有关.
研究的目的:
- 审查亚历山大病的潜在治疗点.
- 为了探索影响GFAP基因表达的药物标.
- 鉴于其神经保护作用,确定可降低GFAP的替代治疗方法.
主要方法:
- 对潜在药物点的文献综述.
- 探索像STAT3,GDNF,NF-kB,LCN-2和LPS这样的途径.
- 分析当前的治疗策略,包括GFAP基因淘汰.
主要成果:
- 几种药物标 (STAT3,GDNF,NF-kB,LCN-2,LPS通路) 显示出调节GFAP表达的潜力.
- 这些目标也在其他神经退行性疾病中进行研究.
- 目前的临床试验侧重于GFAP基因淘汰,这可能会否定GFAP的有益作用.
结论:
- 针对调节GFAP表达的途径为亚历山大病提供了一个有前途的治疗策略.
- 降低GFAP的调节,而不是消除它,可能会保持其神经保护功能.
- 对这些目标的进一步研究可能会导致这种罕见疾病的新治疗方法.
相关概念视频
Targets for Drug Action: Overview
10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
Drug Discovery: Overview
11.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.1K
Principles of Drug Action
8.2K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
8.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827


